Next Article in Journal
Unique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma
Next Article in Special Issue
ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms
Previous Article in Journal
ALK Inhibitors-Induced M Phase Delay Contributes to the Suppression of Cell Proliferation
Previous Article in Special Issue
Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 12
Issue 4
10.3390/cancers12041056
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Reduced Tumorigenicity of Mouse ES Cells and the Augmented Anti-Tumor Therapeutic Effects under Parg Deficiency

by
Yuki Sonoda
1,2,†,
Yuka Sasaki
1,3,†,
Akemi Gunji
4,
Hidenori Shirai
4,
Tomonori Araki
1,2,
Shoji Imamichi
1,3,
Takae Onodera
1,3,
Anna-Margareta Rydén
4,
Masatoshi Watanabe
5,
Jun Itami
6,
Takuya Honda
2,
Kazuto Ashizawa
7,
Kazuhiko Nakao
2 and
Mitsuko Masutani
1,3,4,8,*
1
Department of Molecular and Genomic Biomedicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan
2
Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan
3
Lab of Collaborative Research, Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo 104-0045, Japan
4
Biochemistry Division, National Cancer Center Research Institute, Tokyo 104-0045, Japan
5
Department of Oncologic Pathology, Mie University Graduate School of Medicine, Mie 514-8507, Japan
6
Department of Radiation Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
7
Department of Clinical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan
8
Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2020, 12(4), 1056; https://doi.org/10.3390/cancers12041056
Submission received: 7 April 2020 / Revised: 20 April 2020 / Accepted: 21 April 2020 / Published: 24 April 2020
(This article belongs to the Special Issue PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer)
Browse Figures
Versions Notes

Abstract

:
PolyADP-ribosylation is a post-translational modification of proteins, and poly(ADP-ribose) (PAR) polymerase (PARP) family proteins synthesize PAR using NAD as a substrate. Poly(ADP-ribose) glycohydrolase (PARG) functions as the main enzyme for the degradation of PAR. In this study, we investigated the effects of Parg deficiency on tumorigenesis and therapeutic efficacy of DNA damaging agents, using mouse ES cell-derived tumor models. To examine the effects of Parg deficiency on tumorigenesis, Parg+/+ and Parg−/− ES cells were subcutaneously injected into nude mice. The results showed that Parg deficiency delays early onset of tumorigenesis from ES cells. All the tumors were phenotypically similar to teratocarcinoma and microscopic findings indicated that differentiation spectrum was similar between the Parg genotypes. The augmented anti-tumor therapeutic effects of X-irradiation were observed under Parg deficiency. These results suggest that Parg deficiency suppresses early stages of tumorigenesis and that Parg inhibition, in combination with DNA damaging agents, may efficiently control tumor growth in particular types of germ cell tumors.

1. Introduction

PolyADP-ribosylation is the post-translational modification of proteins, and poly(ADP-ribose) (PAR) polymerase (PARP) family proteins synthesize PAR using NAD as a substrate. Poly(ADP-ribose) glycohydrolase (PARG) is involved in the degradation of PAR as a main enzyme. PARP-1 is activated upon DNA damage and is crucial for preserving genome stability [1]. Activated PARP-1 recognizes DNA strand breaks and is involved in base-excision repair, DNA strand break repair pathways [1].
The process of polyADP-ribosylation of proteins is tightly regulated by the second enzyme in the metabolic pair: PARG and ADP-ribosyl hydrolase3 (ARH3) [2]. PARG reverses the action of PARP by hydrolyzing the glycosidic bonds of PAR to produce ADP-ribose [3,4]. The catalytic capacity of PARG keeps the polyADP-ribosylation of proteins transient; the conversion rate of PAR is measured in minutes [1].
In DNA repair process, PARG is involved in the regulation of base excision repair and DNA strand break repair through the control of XRCC1 function [5]. PARG functional inhibition leads to increase in radiosensitivity in particular types of cells [6,7]. Perturbation of the PARP-1/PARG balance by the over-expression of PARG has been also shown to alter the genome methylation pattern to that of cancer cell types [8].
The importance of PARG in normal development is underscored by the fact that disruption of PARG leads to embryonic lethality [9,10]. PARG enzyme structures have been revealed [11,12,13]. There are several isoforms of PARG, which are produced from a single gene by alterative splicing. The longest (110 kDa, PARG110) and most abundant isoform is located in the nucleus, while the 60 kDa isoform is located in the cytoplasm and mitochondria [14,15,16,17]. Disruption of exon 4, which is common to all PARG isoforms, leads to cell lethality [9]. However, disruption of exons 2–3 abrogates expression of nuclear PARG, but still allows expression of the remaining isoforms [18]. Furthermore, deficiency of the full-length isoform of PARG leads to enhanced cytotoxic sensitivity by causing PAR accumulation, induced by menadione, alkylating agents, endo-toxic shock and γ-irradiation [18,19].
Upon extensive DNA damage, PARP-1 becomes excessively activated and depletes cellular NAD+ to polyADP-ribosylate proteins. PAR accumulation and the depletion of NAD+ severely perturb the energy balance of cells and lead to apoptosis. PAR accumulation also triggers AIF (apoptosis inducing factor) activation in mitochondria and induces parthanotos, which can be observed in neuronal and cancer cells [20,21]. In heterozygously knockout mice of Parg, suppression of lung cancer development has been reported [22].
As described above, the cytoprotective role of PARG through its involvement in DNA repair in normal cells has been suggested, whereas the functional inhibition of PARG is reported to cause sensitization to DNA-damaging agents in cancer cells. Therefore, PARG may be considered both a tumor suppressor and a therapeutic target of cancer. The accumulated evidence thus led us to hypothesize that PARG may impact both cancer development and cancer therapy. Meanwhile, embryonic stem (ES) cells of mice can be useful as experimental systems for tumorigenesis and teratocarcinoma. In this study, using hypomorphic Parg knockout ES cells, we investigated the effects of Parg deficiency on tumorigenesis and the therapeutic efficacy of DNA damaging agents using ES cell derived tumor models.

2. Results

2.1. Parg−/− ES Cells Show Delayed Tumor Development

We previously generated two hypomorphic Parg−/− ES cell clones, D79 and D122, which retained about 10% residual PARG activity compared to parental wild-type J1 ES cells [7]. The growth rates of these Parg−/− and J1 ES cells are similar in the absence of DNA damaging agents. To examine the effects of Parg deficiency on tumorigenesis, Parg+/+ J1 and two D79 and D122 Parg−/− ES cells were subcutaneously injected into the flanks of nude mice. Following injection, tumor size development was observed weekly over four weeks. An initial delay of tumor growth was observed at weeks two and three in tumors derived from Parg−/− ES cells (p < 0.01, Figure 1). This effect was observed during only the early phase, as tumor size did not differ significantly between the genotypes at week four. These results indicate that PARG deficiency delays the early onset of tumorigenesis derived from ES cells.

2.2. Characterization of Tumor Tissues

To further characterize the tumorigenesis, histological evaluation of HE-stained tumor sections was carried out. Comparison of tissues and cell type are summarized in Table 1. Tumors observed four weeks after injection into nude mice showed ectodermal, mesodermal and endodermal tissue derivatives. Both undifferentiated and differentiated germinal components were detected. Histopathological examination at four weeks identified all tumors as immature teratoma, partially accompanying embryonal carcinoma components. Microscopically, the tumors showed heterogeneous components, especially containing immature neuroectodermal tissue in the form of primitive neuroepithelial rosettes and tubules (Figure 2B,C).
We previously observed that tumors derived from Parp1−/− ES cells showed differentiation into trophoblast lineages, including trophoblast giant cells [23]. Microscopic findings from the tumors derived from Parg−/− ES cells showed no such components, suggesting that in the hypomorphic Parg deficient state, marked differentiation alterations did not occur (Table 1).

2.3. Time Course Analysis of Tumorigenesis

To evaluate the defect in early stage tumorigenesis under Parg deficiency, further histological analyses were performed on sections of tumor tissues (Figure 2A,B). At one and two weeks after injection, tumors derived from Parg−/− ES cells showed a higher tendency of necrosis. The density of tumor cells and stromal cells appeared to be lower in the Parg−/− tumors. As shown in Figure 2B, comparison of percentage of hematoxylin-positive regions in the tumors at four weeks (Figure S1) showed the augmented hematoxylin-positivity, namely hyperchromatic areas (typical areas are shown as Figure 2B), in Parg−/− tumors with a statistical significance. It may suggest that the chromatin density of the cells was higher, possibly reflecting differences in the chromatin state or cell properties.
To characterize the properties of differentiated cells and hyperchromatic components further, we performed the immunostaining analysis for the tumors at four weeks with antibodies against beta-III-tubulin, ectoderm marker; AFP, endoderm marker; TRA-1-60, pluripotent marker, and Brachyury, mesoderm marker. As shown in Figure 2C, immunohistochemical analysis showed beta-III tubulin-positive staining of immature neuroepithelial tissues in both wild-type and Parg−/− tumors. It is, therefore, implied that hyperchromic regions may consist of both ectodermal and endodermal differentiated tissues. The pluripotent marker TRA-1-60 showed higher tendencies of diffused staining in the stromal components of the Parg−/− tumor compared with the wild-type tumor. For the mesoderm marker Brachyury, a higher tendency of staining was also observed in the cell components of Parg−/− tumor. On the other hand, AFP-positive staining patterns of teratocarcinoma and immature glandular components were similar between Parg−/− and wild-type tumors.
We also analyzed whether PAR accumulation occurs in Parg−/− tumors, due to hypomorphic Parg activity. As presented in Figure 2D panels, PAR staining was observed occasionally in the cell nuclei of the Parg−/− tumors but not in the Parg+/+ tumor. This elevated level of PAR confirmed the defect of Parg activity.

2.4. Augmented Anti-Tumor Therapeutic Effects under Parg Deficiency

Previous reports describe that Parg 110 deficient animals are more sensitive to MMS treatment and γ-irradiation compared to wild-type mice [18,19]. Hypomorphic Parg−/− ES cells and particular human cancer cells with PARG knocked down also showed increased sensitivity to DNA-damaging agents, such as alkylating agents and γ-irradiation. Therefore, we first treated ES cells in vitro with MMS and γ-irradiation, and three hours later, the cells were subcutaneously injected to nude mice to observe the tumor growth. As shown in Figure 3A,B, reflecting the in vitro higher sensitivity of Parg−/− ES cells, the tumor growth is delayed for at least 2–3 weeks after treatment with both MMS and 6 Gy γ-irradiation.
Next, we carried out therapeutic models of local X-irradiation using tumors derived from wild-type and Parg−/− ES cells. As shown in Figure 4A–D, when the tumors derived from Parg−/− ES cells D79 and D122 were X-irradiated at the single dose of 7 Gy, they showed a delay in tumor growth. In contrast, when the tumors derived from wild-type J1 ES cells were X-irradiated, delay in tumor growth was not clearly observed. It is thus suggested that the therapeutic efficacy of X-irradiation could be higher in the tumors harboring Parg deficiency.
These results suggest that Parg inhibition in combination with DNA damaging agents may efficiently control tumor growth in particular types of germ cell tumors.

3. Discussion

Our findings demonstrate that Parg deficiency delays the early onset of cancer in vivo in teratocarcinoma model. This suggests that PARG might be an attractive therapeutic target in cancer control of germ cell tumors. The therapeutic model used in this study showed that X-irradiation is more effective in tumors with Parg deficiency compared to wild-type cells.
ES cells are derived from normal cells and their tumor models are phenotypically close to teratocarcinoma and teratoma. It is reported that tumorigenicity of ES cells is driven by oncogene action of E-Ras gene [24], and the genes including PI(3)K [24] and c-Jun [25], Cox1/2 [26] and Oct3/4 [27] are involved in the tumorigenesis process. The present study implies that Parg could be a candidate target for the suppression of tumorigenesis at early stages.
In the subcutaneous injection model of ES cells used herein, ES cells should be grown in spheroids or attached to extracellular matrix in subcutaneous regions. During the stressed period of early tumorigenesis, the presence of Parg was suggested to enhance cell survival. In cultured Parg−/− ES cells, the PAR degradation activity was decreased to 10% of wild-type ES cells [7]. We observed that PAR staining was observed occasionally in the cell nuclei of the Parg−/− tumors but not in the Parg+/+ tumors. This accumulation of PAR confirmed the defect in Parg activity. The infrequent accumulation of PAR may explain the advance of tumor growth in Parg−/− tumors at four weeks, as efficient PAR degradation may be necessary for proliferation. The pluripotency marker staining of Parg−/− tumors at four weeks was also observed in a scattered manner, suggesting that the presence of a majority of differentiated tissues could be related to the infrequent accumulation of PAR in Parg−/− tumors, as differentiated cells are reported to have low levels of PAR compared with proliferating cells [1]. The occasional increase in PAR staining in Parg−/− tumors could be possibly due to the presence of S-phase cells with stalled replication forks [28], leading to a lower proliferation activity. Another possibility could be an increased expression of other PAR degradation enzymes, such as ARH3 in the differentiated tumors. The clarification of the relationship between PAR accumulation and cell proliferation needs to be addressed in further studies.
When we added further stress with alkylating agents and γ-irradiation to ES cells (Figure 3A,B), tumor development was further suppressed under Parg deficiency. This was consistent with our previous observation that when Parg was inhibited in ES cells, caspase-dependent apoptosis was enhanced with S-phase arrest and PAR accumulation after MMS treatment [29].
In diseases, PARP-1 has been shown to be involved in stroke, ischemia diabetes and other inflammatory diseases [30]. PARP-1 is frequently overexpressed in various types of cancers [31,32,33]. As PARG has an opposing enzymatic activity to PARP-1, it is reasonable to hypothesize a similar involvement in disease categories. The involvement of PARG in cancer development has not been extensively studied. However, recent genome sequencing approach accumulated the information of PARG gene mutations in various types of cancer. As shown in Figure 5, the data from TCGA database (A) and CanSAR database (B) showed that PARG gene mutations are present in particular types of cancers and of note, deep deletions could be observed in non-seminomatous germ cell tumors, melanoma, and well-differentiated thyroid cancers, possibly indicating PARG-deficient state. On the other hand, esophageal squamous cell carcinoma, cholangiocarcinoma, bladder urothelial carcinoma, thymic epithelial tumors and diffuse glioma show amplification of PARG gene, possibly suggesting the overexpression of PARG. In fact, PARG activity is reported to be high in C6 glioma tumor cells [34]. With further clinical and basic studies, PARG-deficiency and PARG-overexpression may become useful biomarkers for therapeutic selection and monitoring.
Functional inhibition of PARG in pancreatic cancer cells, which has p53 pathway inactivation, enhanced the necrotic cell death after MMS treatment [29], suggesting that PARG could be a therapeutic target in certain types of cancer cells. It is reported that ovarian cancer cells show differential sensitivity to PARG and PARP inhibitors, and cells with replication vulnerability show persistent replication fork stalling and replication catastrophe, with treatment of the PARG inhibitor and sensitization to CHK1 inhibitor [35].
Whilst the hypomorphic ES cells used in this study show PARG activity of residual 10%, the cell growth was not reduced compared to wild-type ES cells [29], suggesting that ES cells may not be replication vulnerable cells. Parg deficient ES cells also showed a higher sensitivity to cisplatin, but not to topoisomerase I inhibitor, campthothecan and hydrogen peroxide [36].
PARG is involved not only in the DNA repair pathway but also in various cell physiological processes, including epigenetic regulation [8], microRNA regulation and RNA splicing. Pancreatic ductal adenocarcinoma cells expressing pro-oncogenic mRNA stability factor HuR (ELAVL1) show sensitization to oxaliplatin and 5-fluorouracil through persistent PARylation [37]. Silencing of PARG by shRNA decreased the proliferation rate twofold over wild type LoVo colon cancer cells [38]. PARG function was also suggested to be involved in MAP kinase cascade regulation, as implicated by the synthetic lethal effect under PARG and DUSP22 double dysfunction [39]. The mechanism for delayed tumor formation process under Parg deficiency in ES cells should be further analyzed from multiple physiological aspects.

4. Materials and Methods

4.1. Cell Culture

The cell lines used were cultured at 37 °C in a humidified incubator, where CO2 levels were kept at 5%. ES cells were cultured in Dulbecco’s modified Eagle’s medium (Life Technologies Corp., Carlsbad, CA, USA) supplemented with 20% fetal bovine serum, non-essential amino acids (Life Technologies Corp.), 55 µM β-mercaptoethanol, 0.3 mM each of adenosine, guanosine, and thymidine, 0.1 mM uridine, and 1 × 103 U/mL mouse LIF (Chemicon International Inc., Temecula, CA, USA) on gelatin-coated dishes (Asahi Glass Co. Ltd., Tokyo, Japan). Mouse ES cell J1 established from 129Sv/J mouse was provided by Dr. Ochiya of National Cancer Center Research Institute [42]. Hypomorphic two Parg−/− ES cell clones, D122 and D79, which we previously established [7], were used in this study. MMS (Sigma-Aldrich Co., St. Louis, MO, USA) was prepared in saline before use and sterilized by filtration.

4.2. Tumorigenesis Analysis

ES cells (J1, D122 and D79) cultured in the absence of a STO feeder layer [42] were trypsinized and 1 × 107 cells (Figure 1 and Figure 3) or 5 × 106 cells (Figure 4) were subcutaneously injected into both legs of male BALB/c-nu/nu mice (CLEA Japan, Tokyo). The growth of tumors was measured continuously every 3–4 days. Four weeks after injection of ES cells, mice were euthanized and each tumor was histologically analyzed. The tumor volumes were calculated with the following formula: (smallest diameter)2 × (largest diameter)/2. For the time course experiment, mice were euthanized at 7 and 14 days after subcutaneously injection of ES cell. Local X-ray irradiation of the tumors on hind legs were carried out with an X-ray machine (CP-160, 160-kVp, Faxitron X-Ray Corp., Tucson, AZ, USA) using radiation shield of lead. Tumors of one of the hind leg pair were subjected to local X–irradiation with a single dose at 7 Gy (Figure 4, A and C: n = 7 for wild-type (J1), n = 8 for Parg−/− (D79). B and D: n = 9 for wild-type (J1) and Parg−/− (D122)). Tumor growth of non-irradiation controls (Control) was monitored for non-irradiated side of hind leg pair. All animal experiments were approved by the Institutional Animal Experiment Committee of National Cancer Center Research Institute (T05-053-C01, A377-16, T17-053). All animal works were conducted according to relevant national and international guidelines for animal welfare.

4.3. Histological Analysis

After resection of the tumors, they were fixed in neutralized 10% formalin solution and embedded in paraffin blocks using standard procedures. Paraffin sections were stained with hematoxylin-eosin (HE), and histopathological analysis was performed under a light microscopic observation. Tissue sections mounted on slides were also subjected to immunostaining after deparaffinization and rehydration, and antigen retrieval, according to the manufacturer’s protocol. Antibodies used in this study were anti-beta-III-tubulin (Abcam, ab264113, Cambridge, UK), anti-AFP (α-fetoprotein, Pierce, PA5-21004, Shreveport, LA, USA), anti-TRA-1-60 (Santa Cruz, sc-21705, Dallas, TX, USA), Brachyury (Santa Cruz, sc-374321, Dallas, TX, USA) and anti-PAR (BD Pharmingen, Franklin Lakes, NJ, USA). After several washes with PBS, bound antibodies were visualized using 3, 3′-diaminobenzidine according to the manufacturer’s protocol. The sections were counterstained with hematoxylin and mounted.

4.4. Statistical Analysis

Statistical analysis was carried out by the One-way ANOVA test, Mann–Whitney U tests, Turkey’s test and Student t-tests using either SPSS Statistics of Macintosh version (IBM corporation, Armonk, NY, USA), JMP (SAS Institute Inc. Cary, NC, USA) or GraphPad Prizm7 (GraphPad Software Inc., San Diego, CA, USA).

5. Conclusions

In conclusion, our results demonstrate that Parg deficiency delayed the onset of tumor formation of ES cells and augmented anti-tumor therapeutic effects of DNA-damaging agents, including alkylating agents and x- ray irradiation. These results suggest that the inhibition of PARG is likely to be an option for the therapeutic and prophylactic target of cancer control. Some specific inhibitors for PARG have been reported [43,44,45], although clinical studies for therapeutic agents are yet to take place. PARG inhibitors, in combination with DNA-damaging agents, may efficiently suppress tumor growth in particular types of germ cell tumors.

Supplementary Materials

The following are available online at https://www.mdpi.com/2072-6694/12/4/1056/s1, Figure S1: Hematoxylin-eosin staining of tumor tissues derived from mouse ES cells 4 weeks after injection.

Author Contributions

Conceptualization, M.M.; Methodology, A.G., H.S., Y.S. (Yuka Sasaki), T.O., S.I., M.M.; Validation, A.G., H.S., Yuka Sasaki, A.-M.R., T.A., T.O., S.I., M.W., M.M.; Investigation, Y.S. (Yuki Sonoda), Y.S. (Yuka Sasaki), A.G., H.S., T.A., T.O., S.I., M.W., M.M.; Resources, J.I., K.A., K.N., M.M.; Data curation, Y.S. (Yuki Sonoda), Y.S. (Yuka Sasaki), A.G., H.S., A.-M.R., T.A., S.I., M.M.; Writing—Original draft preparation, Y.S. (Yuki Sonoda), Y.S. (Yuka Sasaki), T.A., T.O., S.I., M.M.; Writing—Review and editing, T.H., J.I., K.A., K.N.; Visualization, Y.S. (Yuki Sonoda), Y.S. (Yuka Sasaki), M.M.; Supervision, M.M., T.H., K.N.; Project administration, M.M.; Funding acquisition, K.A., Y.S. (Yuka Sasaki), M.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded in part by a Grant-in-Aid for the Second Term Comprehensive 10-Year Strategy for Cancer Control, a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan, a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, Sports, and Culture of Japan (15025274) and Grant-in-Aids from Foundation for Promotion of Cancer Research and Taiju Life Social Welfare Foundation.

Acknowledgments

We are grateful to Toshio Imai, Tadashige Nozaki, Shozo Takayama, M. Yanagihara, Hitoshi Nakagama, and Takashi Sugimura for valuable suggestions. We thank for technical assistance by Hideki Ogino and Masako Ichishi.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Schreiber, V.; Dantzer, F.; Ame, J.C.; de Murcia, G. Poly(ADP-ribose): Novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7, 517–528. [Google Scholar] [CrossRef] [PubMed]
  2. Oka, S.; Kato, J.; Moss, J. Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J. Biol. Chem. 2006, 281, 705–713. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Ame, J.C.; Jacobson, E.L.; Jacobson, M.K. Molecular heterogeneity and regulation of poly(ADP-ribose) glycohydrolase. Mol. Cell Biochem. 1999, 193, 75–81. [Google Scholar] [CrossRef] [PubMed]
  4. Miwa, M.; Sugimura, T. Splitting of the ribose-ribose linkage of poly(adenosine diphosphate-robose) by a calf thymus extract. J. Biol. Chem. 1971, 246, 6362–6364. [Google Scholar]
  5. Wei, L.; Nakajima, S.; Hsieh, C.L.; Kanno, S.; Masutani, M.; Levine, A.S.; Yasui, A.; Lan, L. Damage response of XRCC1 at sites of DNA single strand breaks is regulated by phosphorylation and ubiquitylation after degradation of poly(ADP-ribose). J. Cell Sci. 2013, 126, 4414–4423. [Google Scholar] [CrossRef] [Green Version]
  6. Nakadate, Y.; Kodera, Y.; Kitamura, Y.; Tachibana, T.; Tamura, T.; Koizumi, F. Silencing of poly(ADP-ribose) glycohydrolase sensitizes lung cancer cells to radiation through the abrogation of DNA damage checkpoint. Biochem. Biophys. Res. Commun. 2013, 441, 793–798. [Google Scholar] [CrossRef]
  7. Shirai, H.; Fujimori, H.; Gunji, A.; Maeda, D.; Hirai, T.; Poetsch, A.R.; Harada, H.; Yoshida, T.; Sasai, K.; Okayasu, R.; et al. Parg deficiency confers radio-sensitization through enhanced cell death in mouse ES cells exposed to various forms of ionizing radiation. Biochem. Biophys. Res. Commun. 2013, 435, 100–106. [Google Scholar] [CrossRef]
  8. Zampieri, M.; Passananti, C.; Calabrese, R.; Perilli, M.; Corbi, N.; De Cave, F.; Guastafierro, T.; Bacalini, M.G.; Reale, A.; Amicosante, G.; et al. Parp1 Localizes within the Dnmt1 Promoter and Protects Its Unmethylated State by Its Enzymatic Activity. PLoS ONE 2009, 4, e4717. [Google Scholar] [CrossRef]
  9. Koh, D.W.; Dawson, V.L.; Dawson, T.M. The road to survival goes through PARG. Cell Cycle. 2005, 4, 397–399. [Google Scholar] [CrossRef]
  10. Chen, L.; Gunji, A.; Uemura, A.; Fujihara, H.; Nakamoto, K.; Onodera, T.; Sasaki, Y.; Imamichi, S.; Isumi, M.; Nozaki, T.; et al. Development of renal failure in PargParp-1 null and Timm23 hypomorphic mice. Biochem. Pharmacol. 2019, 167, 116–124. [Google Scholar] [CrossRef]
  11. Slade, D.; Dunstan, M.S.; Barkauskaite, E.; Weston, R.; Lafite, P.; Dixon, N.; Ahel, M.; Leys, D.; Ahel, I. The structure and catalytic mechanism of a poly(ADP-ribose) glycohydrolase. Nature 2011, 477, 616–620. [Google Scholar] [CrossRef] [PubMed]
  12. Tucker, J.A.; Bennett, N.; Brassington, C.; Durant, S.T.; Hassall, G.; Holdgate, G.; McAlister, M.; Nissink, J.W.; Truman, C.; Watson, M. Structures of the human poly (ADP-ribose) glycohydrolase catalytic domain confirm catalytic mechanism and explain inhibition by ADP-HPD derivatives. PLoS ONE 2012, 7, e50889. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Wang, Z.; Gagne, J.P.; Poirier, G.G.; Xu, W. Crystallographic and biochemical analysis of the mouse poly(ADP-ribose) glycohydrolase. PLoS ONE 2014, 9, e86010. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Poitras, M.F.; Koh, D.W.; Yu, S.W.; Andrabi, S.A.; Mandir, A.S.; Poirier, G.G.; Dawson, V.L.; Dawson, T.M. Spatial and functional relationship between poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in the brain. Neuroscience 2007, 148, 198–211. [Google Scholar] [CrossRef] [Green Version]
  15. Meyer-Ficca, M.L.; Meyer, R.G.; Coyle, D.L.; Jacobson, E.L.; Jacobson, M.K. Human poly(ADP-ribose) glycohydrolase is expressed in alternative splice variants yielding isoforms that localize to different cell compartments. Exp. Cell Res. 2004, 297, 521–532. [Google Scholar] [CrossRef]
  16. Burns, D.M.; Ying, W.; Kauppinen, T.M.; Zhu, K.; Swanson, R.A. Selective Down-Regulation of Nuclear Poly(ADP-Ribose) Glycohydrolase. PLoS ONE 2009, 4, e4896. [Google Scholar] [CrossRef] [Green Version]
  17. Whatcott, C.J.; Meyer-Ficca, M.L.; Meyer, R.G.; Jacobson, M.K. A specific isoform of poly(ADP-ribose) glycohydrolase is targeted to the mitochondrial matrix by a N-terminal mitochondrial targeting sequence. Exp. Cell Res. 2009, 315, 3477–3485. [Google Scholar] [CrossRef] [Green Version]
  18. Cortes, U.; Tong, W.M.; Coyle, D.L.; Meyer-Ficca, M.L.; Meyer, R.G.; Petrilli, V.; Herceg, Z.; Jacobson, E.L.; Jacobson, M.K.; Wang, Z.Q. Depletion of the 110-kilodalton isoform of poly(ADP-ribose) glycohydrolase increases sensitivity to genotoxic and endotoxic stress in mice. Mol. Cell Biol. 2004, 24, 7163–7178. [Google Scholar] [CrossRef] [Green Version]
  19. Koh, D.W.; Lawler, A.M.; Poitras, M.F.; Sasaki, M.; Wattler, S.; Nehls, M.C.; Stoger, T.; Poirier, G.G.; Dawson, V.L.; Dawson, T.M. Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proc. Natl. Acad. Sci. USA 2004, 101, 17699–17704. [Google Scholar] [CrossRef] [Green Version]
  20. Yu, S.W.; Wang, H.; Poitras, M.F.; Coombs, C.; Bowers, W.J.; Federoff, H.J.; Poirier, G.G.; Dawson, T.M.; Dawson, V.L. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002, 297, 259–263. [Google Scholar] [CrossRef]
  21. Andrabi, S.A.; Kim, N.S.; Yu, S.W.; Wang, H.; Koh, D.W.; Sasaki, M.; Klaus, J.A.; Otsuka, T.; Zhang, Z.; Koehler, R.C.; et al. Poly(ADP-ribose) (PAR) polymer is a death signal. Proc. Natl. Acad. Sci. USA 2006, 103, 18308–18313. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Dai, W.; Fu, Y.; Deng, Y.; Zeng, Z.; Gu, P.; Liu, H.; Liu, J.; Xu, X.; Wu, D.; Luo, X.; et al. Regulation of Wnt Singaling Pathway by Poly (ADP-Ribose) Glycohydrolase (PARG) Silencing Suppresses Lung Cancer in Mice Induced by Benzo(a)pyrene Inhalation Exposure. Front. Pharmacol. 2019, 10, 338. [Google Scholar] [CrossRef] [PubMed]
  23. Nozaki, T.; Masutani, M.; Watanabe, M.; Ochiya, T.; Hasegawa, F.; Nakagama, H.; Suzuki, H.; Sugimura, T. Syncytiotrophoblastic giant cells in teratocarcinoma-like tumors derived from Parp-disrupted mouse embryonic stem cells. Proc. Natl. Acad. Sci. USA 1999, 96, 13345–13350. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Takahashi, K.; Mitsui, K.; Yamanaka, S. Role of ERas in promoting tumour-like properties in mouse embryonic stem cells. Nature 2003, 423, 541–545. [Google Scholar] [CrossRef]
  25. Hilberg, F.; Wagner, E.F. Embryonic stem (ES) cells lacking functional c-jun: Consequences for growth and differentiation, AP-1 activity and tumorigenicity. Oncogene 1992, 7, 2371–2380. [Google Scholar]
  26. Zhang, X.; Morham, S.G.; Langenbach, R.; Baggs, R.B.; Young, D.A. Lack of cyclooxygenase-2 inhibits growth of teratocarcinomas in mice. Exp. Cell Res. 2000, 254, 232–240. [Google Scholar] [CrossRef]
  27. Gidekel, S.; Pizov, G.; Bergman, Y.; Pikarsky, E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003, 4, 361–370. [Google Scholar] [CrossRef] [Green Version]
  28. Bryant, H.E.; Petermann, E.; Schultz, N.; Jemth, A.S.; Loseva, O.; Issaeva, N.; Johansson, F.; Fernandez, S.; McGlynn, P.; Helleday, T. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 2009, 28, 2601–2615. [Google Scholar] [CrossRef] [Green Version]
  29. Shirai, H.; Poetsch, A.R.; Gunji, A.; Maeda, D.; Fujimori, H.; Fujihara, H.; Yoshida, T.; Ogino, H.; Masutani, M. PARG dysfunction enhances DNA double strand break formation in S-phase after alkylation DNA damage and augments different cell death pathways. Cell Death Dis. 2013, 4, e656. [Google Scholar] [CrossRef]
  30. Virág, L.; Szabó, C. The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors. Pharmacol. Rev. 2002, 54, 375–429. [Google Scholar] [CrossRef]
  31. Gonçalves, A.; Finetti, P.; Sabatier, R.; Gilabert, M.; Adelaide, J.; Borg, J.-P.; Chaffanet, M.; Viens, P.; Birnbaum, D.; Bertucci, F. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: A meta-analysis. Breast Cancer Res. Treat. 2011, 127, 273–281. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Nosho, K.; Yamamoto, H.; Mikami, M.; Taniguchi, H.; Takahashi, T.; Adachi, Y.; Imamura, A.; Imai, K.; Shinomura, Y. Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur. J. Cancer 2006, 42, 2374–2381. [Google Scholar] [CrossRef] [PubMed]
  33. Staibano, S.; Pepe, S.; Muzio, L.L.; Somma, P.; Mascolo, M.; Argenziano, G.; Scalvenzi, M.; Salvatore, G.; Fabbrocini, G.; Molea, G.; et al. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum. Pathol. 2005, 36, 724–731. [Google Scholar] [CrossRef] [PubMed]
  34. Sevigny, M.B.; Silva, J.M.; Lan, W.C.; Alano, C.C.; Swanson, R.A. Expression and activity of poly(ADP-ribose) glycohydrolase in cultured astrocytes, neurons, and C6 glioma cells. Brain Res. Mol. Brain Res. 2003, 117, 213–220. [Google Scholar] [CrossRef]
  35. Pillay, N.; Tighe, A.; Nelson, L.; Littler, S.; Coulson-Gilmer, C.; Bah, N.; Golder, A.; Bakker, B.; Spierings, D.C.J.; James, D.I.; et al. DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors. Cancer Cell 2019, 35, 519–533. [Google Scholar] [CrossRef] [Green Version]
  36. Fujihara, H.; Ogino, H.; Maeda, D.; Shirai, H.; Nozaki, T.; Kamada, N.; Jishage, K.; Tanuma, S.; Takato, T.; Ochiya, T.; et al. Poly(ADP-ribose) Glycohydrolase deficiency sensitizes mouse ES cells to DNA damaging agents. Curr. Cancer Drug Targets 2009, 9, 953–962. [Google Scholar] [CrossRef]
  37. Jain, A.; Agostini, L.C.; McCarthy, G.A.; Chand, S.N.; Ramirez, A.; Nevler, A.; Cozzitorto, J.; Schultz, C.W.; Lowder, C.Y.; Smith, K.M.; et al. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Cancer Res. 2019, 79, 4491–4502. [Google Scholar] [CrossRef]
  38. Fauzee, N.J.; Li, Q.; Wang, Y.L.; Pan, J. Silencing Poly (ADP-Ribose) Glycohydrolase (PARG) Expression Inhibits Growth of Human Colon Cancer Cells In Vitro via PI3K/Akt/NFkappa-B Pathway. Pathol. Oncol. Res. 2011. [Google Scholar] [CrossRef]
  39. Sasaki, Y.; Fujimori, H.; Hozumi, M.; Onodera, T.; Nozaki, T.; Murakami, Y.; Ashizawa, K.; Inoue, K.; Koizumi, F.; Masutani, M. Dysfunction of Poly (ADP-Ribose) Glycohydrolase Induces a Synthetic Lethal Effect in Dual Specificity Phosphatase 22-Deficient Lung Cancer Cells. Cancer Res. 2019, 79, 3851–3861. [Google Scholar] [CrossRef]
  40. cBioPortal for Cancer Genomics. Available online: https://www.cbioportal.org (accessed on 30 December 2019).
  41. CanSAR database. Available online: https://cansarblack.icr.ac.uk/ (accessed on 29 December 2019).
  42. Masutani, M.; Nozaki, T.; Nishiyama, E.; Ochiya, T.; Wakabayashi, K.; Suzuki, H.; and Sugimura, T. Establishment of poly(ADP-ribose) polymerase-deficient mouse embryonic stem cell lines. Proc. Jpn. Acad. 1998, 74, 233–236. [Google Scholar] [CrossRef] [Green Version]
  43. Islam, R.; Koizumi, F.; Kodera, Y.; Inoue, K.; Okawara, T.; Masutani, M. Design and synthesis of phenolic hydrazide hydrazones as potent poly(ADP-ribose) glycohydrolase (PARG) inhibitors. Bioorg. Med. Chem. Lett. 2014, 24, 3802–3806. [Google Scholar] [CrossRef] [PubMed]
  44. Gogola, E.; Duarte, A.A.; de Ruiter, J.R.; Wiegant, W.W.; Schmid, J.A.; de Bruijn, R.; James, D.I.; Llobet, S.G.; Vis, D.J.; Annunziato, S.; et al. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. Cancer Cell 2019, 35, 950–952. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Houl, J.H.; Ye, Z.; Brosey, C.A.; Balapiti-Modarage, L.P.F.; Namjoshi, S.; Bacolla, A.; Laverty, D.; Walker, B.L.; Pourfarjam, Y.; Warden, L.S.; et al. Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death. Nat. Commun. 2019, 10, 5654. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Cancers 12 01056 g001 550
Figure 1. Effect of Parg deficiency on tumorigenesis from embryonic stem (ES) cells. In total, 1 × 107 ES cells were inoculated s.c. into nude mice and size of tumors was measured weekly. Wild-type, J1. Parg−/−, D79 and D122.
Figure 1. Effect of Parg deficiency on tumorigenesis from embryonic stem (ES) cells. In total, 1 × 107 ES cells were inoculated s.c. into nude mice and size of tumors was measured weekly. Wild-type, J1. Parg−/−, D79 and D122.
Cancers 12 01056 g001
Cancers 12 01056 g002a 550Cancers 12 01056 g002b 550
Figure 2. Hematoxylin-eosin staining of tumor tissues derived from mouse ES cells. (A) Hematoxylin-eosin staining of tumor tissues derived from mouse ES cells 1 and 2 weeks after injection. Upper panels, wild-type J1. Lower panels, Parg−/−. (B) The left graph shows the percentage of hyperchromatic area of the tumors 4 weeks after injection. Percentage of hematoxylin-positive hyperchromatic area in the total area of tumor section was measured for each tumor. * p < 0.01, ** p < 0.005. Right panels show the typical hyperchromatic areas of hematoxylin-eosin staining of tumors 4 weeks after injection. Upper panels, ×20 magnification (Squares show magnified regions in the lower panels. Lower panels, ×40 magnification. The tumors showed heterogeneous cell components containing primitive neuroepithelial components and embryonal carcinoma components. (C) HE staining and immunostaining of the tumors at 4 weeks with antibodies against b-III-tubulin, ectoderm marker; AFP, endoderm marker (×20 magnification). Hematoxylin-eosin staining, ×10 magnification. The mixed staining pattern of ectodermal and endodermal markers was observed in hyperchromatic regions of Parg−/− tumors at 4 weeks. (D) Immunostaining of the tumors at 4 weeks after injection with antibody against anti-PAR. Right panels in D are magnified images, Bars, 50 mm (left panels in D), 20 mm (right panels in D). PAR staining was observed occasionally in the cell nuclei in the Parg−/− tumor but not in the Parg+/+ tumor.
Figure 2. Hematoxylin-eosin staining of tumor tissues derived from mouse ES cells. (A) Hematoxylin-eosin staining of tumor tissues derived from mouse ES cells 1 and 2 weeks after injection. Upper panels, wild-type J1. Lower panels, Parg−/−. (B) The left graph shows the percentage of hyperchromatic area of the tumors 4 weeks after injection. Percentage of hematoxylin-positive hyperchromatic area in the total area of tumor section was measured for each tumor. * p < 0.01, ** p < 0.005. Right panels show the typical hyperchromatic areas of hematoxylin-eosin staining of tumors 4 weeks after injection. Upper panels, ×20 magnification (Squares show magnified regions in the lower panels. Lower panels, ×40 magnification. The tumors showed heterogeneous cell components containing primitive neuroepithelial components and embryonal carcinoma components. (C) HE staining and immunostaining of the tumors at 4 weeks with antibodies against b-III-tubulin, ectoderm marker; AFP, endoderm marker (×20 magnification). Hematoxylin-eosin staining, ×10 magnification. The mixed staining pattern of ectodermal and endodermal markers was observed in hyperchromatic regions of Parg−/− tumors at 4 weeks. (D) Immunostaining of the tumors at 4 weeks after injection with antibody against anti-PAR. Right panels in D are magnified images, Bars, 50 mm (left panels in D), 20 mm (right panels in D). PAR staining was observed occasionally in the cell nuclei in the Parg−/− tumor but not in the Parg+/+ tumor.
Cancers 12 01056 g002aCancers 12 01056 g002b
Cancers 12 01056 g003 550
Figure 3. Effect of Parg deficiency on tumorigenesis from ES cells pretreated with MMS or γ–irradiation before injection into nude mice. ES cells treated with γ–irradiation at 6 Gy (A) or 0.5 mM MMS (B) and cultured for 3 h, respectively, were inoculated s.c. into nude mice. Tumor growth was observed for four weeks. The bars show the mean size.
Figure 3. Effect of Parg deficiency on tumorigenesis from ES cells pretreated with MMS or γ–irradiation before injection into nude mice. ES cells treated with γ–irradiation at 6 Gy (A) or 0.5 mM MMS (B) and cultured for 3 h, respectively, were inoculated s.c. into nude mice. Tumor growth was observed for four weeks. The bars show the mean size.
Cancers 12 01056 g003
Cancers 12 01056 g004 550
Figure 4. Effect of Parg deficiency on therapeutic efficacy of X–irradiation on tumors derived from ES cells. Tumors of one of the hinder leg pair were subjected to local X–irradiation with a single dose at 7 Gy ((A,C): n = 7 for wild-type (J1), n = 8 for Parg−/− (D79). (B,D): n = 9 for wild-type (J1) and Parg−/− (D122)). Tumor growth of non-irradiation controls (Control) was monitored for non-irradiated side of hinder leg pair. Tumor growth was observed for 22 days. (A,B) Tumor growth curve, Mean ± S. E. (C,D) Measured tumor weight 22 days after injection of ES cells, Mean ± S. E. (C) Statistical analysis was carried out with Turkey’s test. * p < 0.05. (D) Statistical analysis was carried out with Mann–Whitney U-test. * p < 0.01.
Figure 4. Effect of Parg deficiency on therapeutic efficacy of X–irradiation on tumors derived from ES cells. Tumors of one of the hinder leg pair were subjected to local X–irradiation with a single dose at 7 Gy ((A,C): n = 7 for wild-type (J1), n = 8 for Parg−/− (D79). (B,D): n = 9 for wild-type (J1) and Parg−/− (D122)). Tumor growth of non-irradiation controls (Control) was monitored for non-irradiated side of hinder leg pair. Tumor growth was observed for 22 days. (A,B) Tumor growth curve, Mean ± S. E. (C,D) Measured tumor weight 22 days after injection of ES cells, Mean ± S. E. (C) Statistical analysis was carried out with Turkey’s test. * p < 0.05. (D) Statistical analysis was carried out with Mann–Whitney U-test. * p < 0.01.
Cancers 12 01056 g004
Cancers 12 01056 g005 550
Figure 5. PARG mutation frequencies in human cancers. (A) The percentage of nonsynonymous mutation of PARG in each cancer in the TCGA database [40]. (B) The percentage of nonsynonymous substitution mutation of PARG in each cancer (total 165 mutations were listed in tumor samples from 8018 patients.) in the CanSAR database [41].
Figure 5. PARG mutation frequencies in human cancers. (A) The percentage of nonsynonymous mutation of PARG in each cancer in the TCGA database [40]. (B) The percentage of nonsynonymous substitution mutation of PARG in each cancer (total 165 mutations were listed in tumor samples from 8018 patients.) in the CanSAR database [41].
Cancers 12 01056 g005
Table
Table 1. Tissue components in tumors from Parg+/+ and Parg−/− ES cells.
Table 1. Tissue components in tumors from Parg+/+ and Parg−/− ES cells.
Tissue TypeParg+/+(J1)Parg−/− (D79)Parg−/− (D122)
Embryonal carcinoma+++
Hemorrhage−−−
Trophoblast giant cells−−−
Ectodermal derivatives
Primitive neuroepithelium+++
Mature neural tissue+++
Keratinized epithelium+++
Mesodermal derivatives
Cartilage+++
Bone+++
Blood vessel+++
Lymphocyte and blood cell+++
Muscle+++
Endodermal derivatives
Ciliated epithelium+++
Gut epithelium+++

Share and Cite

MDPI and ACS Style

Sonoda, Y.; Sasaki, Y.; Gunji, A.; Shirai, H.; Araki, T.; Imamichi, S.; Onodera, T.; Rydén, A.-M.; Watanabe, M.; Itami, J.; et al. Reduced Tumorigenicity of Mouse ES Cells and the Augmented Anti-Tumor Therapeutic Effects under Parg Deficiency. Cancers 2020, 12, 1056. https://doi.org/10.3390/cancers12041056

AMA Style

Sonoda Y, Sasaki Y, Gunji A, Shirai H, Araki T, Imamichi S, Onodera T, Rydén A-M, Watanabe M, Itami J, et al. Reduced Tumorigenicity of Mouse ES Cells and the Augmented Anti-Tumor Therapeutic Effects under Parg Deficiency. Cancers. 2020; 12(4):1056. https://doi.org/10.3390/cancers12041056

Chicago/Turabian Style

Sonoda, Yuki, Yuka Sasaki, Akemi Gunji, Hidenori Shirai, Tomonori Araki, Shoji Imamichi, Takae Onodera, Anna-Margareta Rydén, Masatoshi Watanabe, Jun Itami, and et al. 2020. "Reduced Tumorigenicity of Mouse ES Cells and the Augmented Anti-Tumor Therapeutic Effects under Parg Deficiency" Cancers 12, no. 4: 1056. https://doi.org/10.3390/cancers12041056

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop